Last reviewed · How we verify
Dental Implant Healing in Patients Taking Tumor Necrosis Factor (TNF)-Alpha Inhibitors
The goal of this pilot study is to learn about healing after dental implant placement in patients taking a class of biologic drug called Tumor Necrosis Factor or TNF-alpha antagonist or inhibitor. The main questions it aims to answer are: Do patients taking TNF-alpha inhibitors have any complications after the placement of dental implants? Do patients taking TNF-alpha inhibitor experience increased pain after dental implant placement compared to the expected levels when healing from this procedure? Researchers will recruit patients both taking these drugs and those not taking these drugs to compare the outcomes between the two groups. Participants missing teeth will be recruited to receive dental implants to meet ideal dental status and will be followed before and after the implant placement to determine levels of health and ensure proper healing. Participants will be followed for a total of one year and follow up visits will consist of both clinical examination and radiographs (x-rays) to evaluate bone level and implant status. Participants will also be asked to rate their pain during clinic visits and at home on a diary and record the amount of pain control medication they take after the implant procedure.
Details
| Lead sponsor | University of Pennsylvania |
|---|---|
| Phase | NA |
| Status | RECRUITING |
| Enrolment | 30 |
| Start date | 2025-06-28 |
| Completion | 2026-12 |
Conditions
- Edentulism
- Dental Implants
- TNF-alpha Inhibitors
Interventions
- Placement of dental implants
Primary outcomes
- Safety of implant placement in patients taking TNF-α inhibitors — Healing will be assessed over 1 year after implant placement
A pilot cohort of patients will be recruited who require implants for standard of care restoration for tooth loss. Patients will be evaluated pre- and post-operatively and followed for 1 year to assess healing using clinical exam.
Countries
United States